Epilepsy Research
Volume 32, Issue 3 , Pages 371-378 , November 1998

Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine

  • M Bialer

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, PO Box 12065, Jerusalem 91120, Israel
    • David R. Bloom Centre for Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of JerusalemPO Box 12065, Jerusalem 91120, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 2 6758610; fax: +972 2 6436246; e-mail: bialer@md2.huji.ac.il
    • ,
  • L Arcavi

      Affiliations

    • Clinical Pharmacology Unit, Department of Internal Medicine, Kaplan Hospital, Rehovot, Israel
    • ,
  • S Sussan

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, PO Box 12065, Jerusalem 91120, Israel
    • ,
  • A Volosov

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, PO Box 12065, Jerusalem 91120, Israel
    • ,
  • A Yacobi

      Affiliations

    • Taro Pharmaceuticals, New York, USA
    • ,
  • D Moros

      Affiliations

    • Taro Pharmaceuticals, New York, USA
    • Department of Neurology, Mount Sinai Medical School, New York, USA
    • ,
  • B Levitt

      Affiliations

    • Taro Pharmaceuticals, New York, USA
    • Department of Medicine, Albert Einstein Medical School, New York, USA
    • ,
  • A Laor

      Affiliations

    • Department of Internal Medicine, Lady Davis Carmel Hospital, Haifa, Israel

Received 11 February 1998 ,Accepted 5 May 1998.

References 

  1. Ahr, G., Shaefer, H.G., 1991. In: Blume, H.H. et al. (Eds.), Controlled/Modified Release Products. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 85–98.
  2. Ahrons L. Assessment of rate of absorption in bioequivalence studies. J. Pharm. Sci. 1987;76:853–855
  3. Bialer M. Pharmacokinetic evaluation of sustained release formulation of antiepileptic drugs. Clin. Pharmacokinet. 1992;22:11–21
  4. Bialer, M., Cloyd, J.C., 1995. Drug formulations and routes of administration. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs, 4th ed. Raven Press, New York, pp. 161–178.
  5. Bonneton J, Iliadis A, Genton P, Dravet C, Viallat D, Mesdjian E. Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy. Epilepsy Res. 1993;14:257–263
  6. Canger R, Altamura AC, Belvedere O, Monaco F, Monza GC, Muscas GC, et al. Conventional vs. controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta. Neurol. Scand. 1990;82:9–13
  7. Dhalla Z, Bruni J, Sutton J. A comparison of the efficacy and tolerability of controlled-release carbamazepine with conventional carbamazepine. Can. J. Neurol. Sci. 1991;18:66–68
  8. Endrenyi L, Fritsch S, Yan WI. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. J. Clin. Pharmacol. Ther. Toxicol. 1991;29:394–399
  9. Endrenyi L, Yan W. Variation of Cmax and Cmax/AUC in investigations of bioequivalence. Int. J. Clin. Pharmacol. Ther. Toxicol. 1993;31:184–189
  10. Endrenyi, L., Tothfalusi, L., 1997. Secondary metrics for the assessments of bioequivalence. J. Pharm. Sci. 88, 401–402.
  11. Gibaldi, M., Perrier, D., 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, New York.
  12. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology. 1993;43:2696–2697
  13. Hartley R, Aleksandrowicz J, Ng PC, McLain B, Bowmer CJ, Forsythe WI. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?. Br. J. Clin. Pract. 1990;44:270–273
  14. Haushke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990;28:72–78
  15. Jackson AJ, Chen M-L. Application of moment analysis in assessing rates of absorption for bioequivalency studies. J. Pharm. Sci. 1987;76:6–9
  16. Kaski M, Heinonen E, Sivenius J, Touminen J, Anttila M. Treatment of epliepsy in mentally retarded patients with a slow-release carbamazepine preparation. J. Ment. Def. Res. 1991;35:231–239
  17. Khoo K-C, Gibaldi M, Brazzell RV. Comparison of statistical moment parameters to Cmax and tmax for detecting differences in in vivo dissolution rates. J. Pharm. Sci. 1985;74:1340–1342
  18. Meier J, Nuesch E, Schmidt R. Pharmacokinetic criteria for the evaluation of retard formulations. Eur. J. Clin. Pharmacol. 1974;7:429–432
  19. Midha KK, Hubbard JW, Rawson M, Gavalas L. The application of partial areas in assessment of rate and extent of absorption. Eur. J. Pharm. Sci. 1994;2:351–363
  20. Neuvonen PJ. Bioavailability and central side effects of different carbamazepine tablets. Int. J. Clin. Pharmacol. Toxicol. 1985;23:226–232
  21. Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology. 1992;42:1147–1152
  22. Pieters MSM, Jennekens-Schinkel A, Stijnen T, Edelbroek PM, Brouwer OF, Liauw L, et al. Carbamazepine (CBZ) controlled release compared with conventional CBZ. A controlled study of attention and vigilence in children with epilepsy. Epilepsia. 1992;33:1137–1144
  23. Pollack PT, Freeman DJ, Carruthers SG. Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations. J. Pharm. Sci. 1988;77:477–480
  24. Richens A. Impact of generic substitution of antiepileptic drugs on the treatment of epilepsy. CNS Drugs. 1997;8:124–133
  25. Riva, R., Contin, M., Albani, F., Perucca, E., Ambrosetto, G., Prucaccianti, G., Santucci, M., Baruzzi, A., 1985. Lateral gaze nystagmus in carbamazepine treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite. Ther. Drug Monit. 187, 277–282.
  26. Rostami-Hadjegan A, Jackson PR, Tucker GTJ. Sensitivity of indirect metrics for assessing `rate' in bioequivalence-moving the `goalposts' or changing the `game'. J. Pharm. Sci. 1994;83:1552–1554
  27. Sachdeo RC, Belendiuk G. Generic versus branded carbamazepine. Lancet. 1987;1:1432
  28. Sachdeo RC, Chokroverty S, Belendiuk G. Risk of switching from brand name to generic drug in seizure disorder. Epilepsia. 1987;28:581
  29. SAS for personal computers, Rel 6.08., Cary, NC.
  30. Schulz H-U, Steinijans VW. Striving for standards in bioequivalence assessment: a review. Int. J. Clin. Pharmacol. Ther. Toxicol. 1991;29:293–298
  31. Schall R, Luus HG. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992;30:153–159
  32. Shapiro SS, Wilk MB. An analysis of varainace test for normality. Biometrika. 1965;52:591–611
  33. Steinijans VW, Hauschke D, Jonkman HHG. Controversies in bioequivalence studies. Clin. Pharmacokinet. 1992;22:247–253
  34. Steinijans VW. Pharmacokinetics characterization of controlled release formulations. Eur. J. Drug Metab. Pharmacokinet. 1991;15:173–181
  35. Steinijans VW, Hauchke D. Statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992;30(Suppl. 1):S45–S50
  36. Studies on bioavailability and bioequivalence, 1987. APV guideline, international views of politics and science with contributions on development, manufacture, marketing, distribution and therapeutic use of drugs. APV: Mainz. 30, 131–136.
  37. The Tegretol Oros Osmotic Release Delivery System Study Group., 1995. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. Neurology 45, 1703–1707.
  38. Theodore WH, Narang PK, Holmes MD, Reeves P, Nice FJ. Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control. Ann. Neurol. 1989;25:194–196
  39. Tomson T. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Arch. Neurol. 1986;41:830–834

PII: S0920-1211(98)00064-3

Epilepsy Research
Volume 32, Issue 3 , Pages 371-378 , November 1998

Article Tools

* Image Usage & Resolution